Pfizer and BioNTech have announced the dosing of the first participants of its US Phase I/II Covid-19 vaccine study. The pair has four vaccine candidates against the novel coronavirus in the BNT162 development programme; a study of these products are already underway in Germany.

Pfizer chairman and CEO Albert Bourla said: “With our unique and robust clinical study program underway, starting in Europe and now the US we look forward to advancing quickly and collaboratively with our partners at BioNTech and regulatory authorities to bring a safe and efficacious vaccine to the patients who need it most.

“The short, less than four-month timeframe in which we’ve been able to move from pre-clinical studies to human testing is extraordinary and further demonstrates our commitment to dedicating our best-in-class resources, from the lab to manufacturing and beyond, in the battle against Covid-19.”